• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Outset Medical at-home dialysis system wins FDA approval

Outset Medical at-home dialysis system wins FDA approval

April 6, 2020 By Sean Whooley

Outset MedicalOutset Medical announced that it won expanded FDA clearance for patient use in the home with its Tablo hemodialysis system.

Tablo’s existing indication included use in acute and chronic care facilities but, amid the COVID-19 pandemic, can now offer hemodialysis treatment from the home as in-hospital treatment is more of a challenge under current circumstances.

Outset’s Tablo system is designed to use wireless data, sensor-based automation and an animated touchscreen to make dialysis care accessible in-home, requiring only an electrical outlet and tap water to operate. The all-in-one dialysis machine, which handles both water purification and dialysate production, is designed to be used in a variety of settings.

“Tablo was designed to simplify dialysis, making it easier and more accessible for patients to take advantage of the safety, convenience and flexibility of dialyzing at home.” Outset Medical CEO Leslie Trigg said in a news release. “We are proud to offer them this new, life-enhancing option, particularly in light of the COVID-19 related challenges dialysis patients and providers are experiencing.”

The demand for in-home dialysis treatment continues to grow after, in July 2019, the Trump administration revealed its plan to overhaul the way kidney disease is treated in the U.S., looking to increase early detection and emphasize transplants and home hemodialysis instead of in-clinic treatment.

In October 2019, Tablo won a contract from the U.S. Dept. of Health & Human Services for use in response to natural disasters. In February of this year, the company announced that it raised $125 million in a Series E equity financing round to help support the commercial expansion of Tablo in the U.S.

Other dialysis treatment developers are adjusting during the COVID-19 pandemic, as Fresenius (NYSE:FMS) and DaVita Healthcare (NYSE:DVA) announced a collaboration to offer isolation capacity for dialysis patients who are or may be COVID-19-positive.

The goal of the collaboration is to maintain continuity of care for dialysis patients and to keep them out of the hospital whenever possible to free up limited hospital resources, according to a news release.

Filed Under: Dialysis, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: FDA, Outset Medical

More recent news

  • Abbott rolls out SimpleScreen colorectal cancer blood test developed by Freenome
  • Terumo to buy Arsenal Medical and its liquid embolic brain bleed system
  • MassDevice parent Arrowfly is launching AI for Engineers
  • Smart ring maker Oura postpones anticipated IPO
  • Medtronic gains regulatory wins for latest cardiac ablation software

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy